Dr. Kristopher Shawn Lybarger, DO

Dr. Lybarger practices at Centerpoint Medical Center in Independence, Missouri, part of HCA Healthcare.

Dr. Lybarger's NPI, 1013172022, was assigned on July 20, 2008. Dr. Lybarger holds Missouri license 2015025644.

Dr. Lybarger's primary practice is Centerpoint Medical Center, at 19600 East 39th Street, Independence, MO 64057 in Jackson County. The practice phone is (816) 698-7000.

Dr. Lybarger's primary practice is Centerpoint Medical Center in Independence, Missouri, part of HCA Healthcare. Dr. Lybarger is also affiliated with Stormont Vail Hospital. The medical group on file is Midwest Oncology Associates. Dmand AI also links Dr. Lybarger to 3 more hospitals, 2 group practices and clinics, 2 medical groups and 1 breast imaging center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lybarger practices, 8 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Lybarger's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dmand AI has Dr. Lybarger's licenses on file in 4 states: Missouri, Kansas, Michigan and Pennsylvania.

CMS data shows 375 Medicare services from Dr. Lybarger across 7 procedure codes in 2024, for 193 Medicare patients. Medicare paid $47,787 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 193 Medicare patients who saw Dr. Lybarger in 2024. The largest group is 65 to 74, with 113 patients. 75% of them have high blood pressure, and 66% have high cholesterol. 13% are also on Medicaid. Their average risk score is 1.76, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lybarger's median patient age at 67, with 99% women.

In 2024, Dr. Lybarger wrote 437 Medicare Part D claims for 129 patients. 95% of them were for generic drugs. CMS names the drug for 362 of them, across 10 drugs with 11 or more claims each, at $230,118 in total drug cost. In 2023, CMS named 187 claims across 7 drugs.

Dr. Lybarger accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Lybarger as offering telehealth. CMS counts 12 procedures of removal of the uterus by Dr. Lybarger, more than 86% of the clinicians it reports for that procedure.

Dmand AI links 3 papers to Dr. Lybarger in 2023. 2023 was the busiest year, with 3. The most frequent topics are Endometrial Neoplasms. Dr. Lybarger's most frequent co-authors are Rebecca Arend, MD, Lisa M. Barroilhet, MD and Cesar M. Castro, MD, MS.

Dmand AI links Dr. Lybarger to 10 clinical trials, 4 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Carcinoma, Ovarian Epithelial, Ovarian Neoplasms and Fallopian Tube Diseases. Open Payments lists research payments to Dr. Lybarger that name 1 trial.

CMS Open Payments shows 1,239 general payments to Dr. Lybarger from 44 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 41% of the total. Davol Inc. paid the most, $342,951. It also lists 2 research payments totaling $9,209 in 2018, naming 1 clinical trial.